Apollo Hospitals Enterprise / Q1-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Positive2025-08-13Back to APOLLOHOSP

Revenue

₹5,842 Cr

verified against source

Revenue YoY

15%

reported change

EBITDA

₹852 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
EBITDA (₹ Cr)PositiveWatchNegative
11 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q1 FY24: 509 · Positive source sentiment · 2023-08-09Q1 FY24Q2 FY24: 628 · Positive source sentiment · 2023-11-14Q2 FY24Q3 FY24: 614 · Positive source sentiment · 2024-01-15Q3 FY24Q4 FY24: 641 · Positive source sentiment · 2024-05-14Q4 FY24Q1 FY25: 675 · Positive source sentiment · 2024-08-14Q1 FY25Q2 FY25: 816 · Positive source sentiment · 2024-11-14Q2 FY25Q3 FY25: 762 · Positive source sentiment · 2025-02-13Q3 FY25Q4 FY25: 770 · Positive source sentiment · 2025-05-10Q4 FY25Q1 FY26: 852 · Positive source sentiment · 2025-08-13Q1 FY26Q2 FY26: 941 · Positive source sentiment · 2025-11-14Q2 FY26Q3 FY26: 965 · Positive source sentiment · 2026-02-14Q3 FY26965509
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Apollo Hospitals delivered a strong Q1 FY26 with consolidated revenue of INR 5,842 crore (+15% YoY) and PAT of INR 433 crore (+42% YoY). Healthcare Services revenue grew 11% to INR 2,935 crore, with EBITDA margins at 24.5% (+88bps YoY). Apollo HealthCo revenue rose 19% to INR 2,472 crore, driven by pharmacy distribution and narrowing digital losses (EBITDA loss of INR 73 crore vs INR 116 crore last year). The company added 700 beds in the pipeline and expects to operationalize them in FY26. Management guided for 13-14% organic hospital growth and Apollo 24/7 breakeven by Q4 FY26. Risk: New hospital ramp-up may cause a ~100bps margin dip in the near term.

Colored figures show movement against the previous available record.

Guidance to track

  • Digital business expected to achieve EBITDA breakeven by end of fiscal year, with GMV run-rate of INR 800-900 crore.
  • New hospitals in Delhi, Pune, Bangalore, and Kolkata to add 700 beds during FY26.
  • Combined entity targeting INR 25,000 crore revenue with 7% EBITDA margin by end of FY27.
  • Existing hospital margins expected to expand to 25%+ before new bed dilution of ~100bps.

Risks flagged

  • Management expects ~100bps margin dip from new hospitals, with total EBITDA impact of INR 100-150 crore over two years.
  • Bangladesh patient flow remains below pre-crisis levels; recovery timeline is uncertain despite new markets like Iraq.
  • Aggressive entry of quick commerce players into prescription medicines could pressure margins and customer acquisition costs.

Key quotes

  • We are well on track to achieve breakeven in the digital business by the end of this fiscal.
  • Incremental players coming in with aggressive strategies, in my mind, will expand the digital market and give a greater amount of trials.
  • We have a plan to move it to 25%. As we look at the losses from new hospitals, total impact over a two-year period could maximum be around INR 150 crore.

Research modules

Go one layer deeper.